These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8446467)

  • 21. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
    Alexander J; Coombs GH; Mottram JC
    J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
    Connell ND; Medina-Acosta E; McMaster WR; Bloom BR; Russell DG
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11473-7. PubMed ID: 8265576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.
    Yang DM; Rogers MV; Liew FY
    Immunology; 1991 Jan; 72(1):3-9. PubMed ID: 1997399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses.
    Pollock KG; McNeil KS; Mottram JC; Lyons RE; Brewer JM; Scott P; Coombs GH; Alexander J
    J Immunol; 2003 Feb; 170(4):1746-53. PubMed ID: 12574338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmania infecting man and wild animals in Saudi Arabia. 8. The influence of prior infection with Leishmania arabica on challenge with L. major in man.
    Peters W; Bryceson A; Evans DA; Neal RA; Kaye P; Blackwell J; Killick-Kendrick R; Liew FY
    Trans R Soc Trop Med Hyg; 1990; 84(5):681-9. PubMed ID: 2126153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania tropica: the identification and purification of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease.
    Lira R; Méndez S; Carrera L; Jaffe C; Neva F; Sacks D
    Exp Parasitol; 1998 Jul; 89(3):331-42. PubMed ID: 9676711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leishmania major: nature of immunity induced by immunization with a mutagenized avirulent clone of the parasite in mice.
    McGurn M; Boon T; Louis JA; Titus RG
    Exp Parasitol; 1990 Jul; 71(1):81-9. PubMed ID: 1972362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis.
    Veras P; Brodskyn C; Balestieri F; Freitas Ld; Ramos A; Queiroz A; Barral A; Beverley S; Barral-Netto M
    Mem Inst Oswaldo Cruz; 1999; 94(4):491-6. PubMed ID: 10446007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role for gamma delta + T cells during experimental infection of mice with Leishmania major.
    Rosat JP; MacDonald HR; Louis JA
    J Immunol; 1993 Jan; 150(2):550-5. PubMed ID: 8419488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L. major in BALB/c mice.
    Onyalo JA; Mwala DM; Anjili CO; Orago AS; Tonui WK
    East Afr Med J; 2005 Apr; 82(4):193-7. PubMed ID: 16122087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration.
    Lezama-Dávila CM
    Arch Med Res; 1997; 28(1):47-53. PubMed ID: 9078587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P
    J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
    Okwor I; Kuriakose S; Uzonna J
    Vaccine; 2010 Jul; 28(33):5451-7. PubMed ID: 20558242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY; Dhaliwal JS
    J Immunol; 1987 Jun; 138(12):4450-6. PubMed ID: 3295049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
    Mendez S; Tabbara K; Belkaid Y; Bertholet S; Verthelyi D; Klinman D; Seder RA; Sacks DL
    Infect Immun; 2003 Sep; 71(9):5121-9. PubMed ID: 12933855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.
    Liew FY; Li Y; Yang DM; Severn A; Cox FE
    Immunology; 1991 Oct; 74(2):304-9. PubMed ID: 1748478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.